Gavin Wood
Director of Finance/CFO at ADAPTIMMUNE THERAPEUTICS PLC
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Helena Tayton-Martin | M | 57 |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | 16 years |
Adrian Rawcliffe | M | 52 | 9 years | |
Giles Kerr | M | 65 | 8 years | |
Elliot Norry | M | 61 | 9 years | |
David Mott | M | 58 | 10 years | |
Margaret Henry | F | - |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | - |
Joanna Brewer | M | 47 | 15 years | |
Michael Baldock | M | 60 | 4 years | |
Ali Behbahani | M | 47 | 10 years | |
Marc Perkins | M | - | 5 years | |
John Furey | M | 59 | 6 years | |
Lawrence Alleva | M | 74 | 9 years | |
William Bertrand | M | 59 | 7 years | |
Sun Yi | M | - | 6 years | |
Phil Bassett | M | - | - | |
Sharp Kerry | F | - | 9 years | |
John Lunger | M | 55 | 7 years | |
Ron Shigeta | M | - | 18 years | |
Juli P. Miller | M | - | 8 years | |
Priti Hegde | M | 52 | 1 years | |
Adrian George Rawcliffe | M | - |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | - |
Kristen Hege | M | 60 | 1 years | |
Garry Menzel | M | 59 | 1 years | |
Andrew Allen | M | 57 | 1 years | |
Dana Lynch | F | - | - |
Connections Chart
Multi-company connection
Former connections
Statistics
Country | Connections | % of total |
---|---|---|
United States | 53 | 56.38% |
United Kingdom | 41 | 43.62% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gavin Wood
- Personal Network